Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Stock Information for Appili Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Appili Therapeutics Inc

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
Evofem Biosciences to Present at Emerging Growth Conference
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.